Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C591
http://purl.obolibrary.org/obo/NCIT_C591
|
|---|---|
| Preferred Name | Recombinant Interleukin-6 |
| Definitions |
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and Ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects. |
|---|---|
| prefLabel | Recombinant Interleukin-6
|
| label | Recombinant Interleukin-6
|
| PDQ_Closed_Trial_Search_ID | 41474
|
| code | C591
|
| Has_Target | |
| prefixIRI | NCIT:C591
|
| in_subset |
See more
See less
|
| Display_Name | Recombinant Interleukin-6
|
| Preferred_Name | Recombinant Interleukin-6
|
| FDA_UNII_Code | 4O4QWG0B3C
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Recombinant Interleukin-6
|
| NCI_Drug_Dictionary_ID | 41474
|
| Legacy Concept Name | Therapeutic_Interleukin-6
|
| type | |
| ALT_DEFINITION | One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-6 is made mainly by some T lymphocytes. It causes B lymphocytes to make more antibodies and also causes fever by affecting areas of the brain that control body temperature. Interleukin-6 made in the laboratory is used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-6 is a type of cytokine.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 41474
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1527132
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |